{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:45Z","timestamp":1791489705561,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatocellular carcinoma (HCC) in autoimmune hepatitis (AIH) was considered rare but is increasing with prolonged prognosis. Its impact on the overall prognosis of AIH is unknown, and treatment has not been established.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To investigate the risk factors and prognosis of HCC in patients with AIH and identify appropriate management strategies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We studied patients with AIH including background liver disease, sex, age, complications, treatment, response to treatment, liver fibrosis, prognosis, and treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 131 patients, deaths due to liver failure were more common early after the onset of AIH; however, deaths due to HCC increased gradually. HCC was observed in 12 patients (median age, 70 years; male\/female, 4\/8; cirrhosis at onset, 11; median time to carcinogenesis, 7 years). Cirrhosis at diagnosis was identified as a risk factor for carcinogenesis in the multivariate analysis (odds ratio, 41.36; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and cumulative cancer rates were high. Multidisciplinary therapy other than immune checkpoint inhibitors was administered as treatment for HCC. Two of the three patients who used molecular-targeted drugs discontinued the treatment because of adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>HCC is an important cause of death in patients with AIH. Currently available drug therapies are limited and early detection is desirable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial was retrospectively registered in the Ethics Committee of Kagawa University School of Medicine under the identifier 2019\u2009\u2212\u2009238, registered on 4 Feb 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-024-03204-z","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T17:01:32Z","timestamp":1711990892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of hepatocellular carcinoma, an important cause of death in Japanese autoimmune hepatitis patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Tomoko","family":"Tadokoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takushi","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Takuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Oura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"issue":"3","key":"3204_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/cam4.1998","volume":"8","author":"K Tarao","year":"2019","unstructured":"Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, Taguri M, Tanaka K. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med. 2019;8(3):1054\u201365.","journal-title":"Cancer Med"},{"key":"3204_CR2","doi-asserted-by":"crossref","unstructured":"Kakehashi A, Suzuki S, Wanibuchi H. Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis. Cancers (Basel) 2023, 15(18).","DOI":"10.3390\/cancers15184566"},{"issue":"5","key":"3204_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3748\/wjg.15.578","volume":"15","author":"A Teufel","year":"2009","unstructured":"Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009;15(5):578\u201382.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3204_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00535-012-0616-x","volume":"48","author":"H Ohira","year":"2013","unstructured":"Ohira H, Abe K, Takahashi A, Zeniya M, Ichida T. Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan. J Gastroenterol. 2013;48(1):109\u201314.","journal-title":"J Gastroenterol"},{"issue":"2","key":"3204_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","volume":"168","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of Immune checkpoint inhibitors in the treatment of patients with Cancer and Preexisting Autoimmune Disease: a systematic review. Ann Intern Med. 2018;168(2):121\u201330.","journal-title":"Ann Intern Med"},{"issue":"7","key":"3204_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2217\/imt-2019-0184","volume":"12","author":"P Bhave","year":"2020","unstructured":"Bhave P, Pham A, Gordon A, Moore M. Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis. Immunotherapy. 2020;12(7):445\u201350.","journal-title":"Immunotherapy"},{"issue":"2","key":"3204_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and management of Autoimmune Hepatitis in adults and children: 2019 Practice Guidance and Guidelines from the American Association for the study of Liver diseases. Hepatology. 2020;72(2):671\u2013722.","journal-title":"Hepatology"},{"issue":"5","key":"3204_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929\u201338.","journal-title":"J Hepatol"},{"issue":"5","key":"3204_CR9","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/hep.22825","volume":"49","author":"P Muratori","year":"2009","unstructured":"Muratori P, Granito A, Pappas G, Muratori L. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology. 2009;49(5):1782\u20133. author reply 1783.","journal-title":"Hepatology"},{"issue":"6","key":"3204_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cgh.2010.03.004","volume":"8","author":"EM Kuiper","year":"2010","unstructured":"Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2010;8(6):530\u20134.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"3204_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Torriani MSS, Dieterich FJ, Thomas DT. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"6","key":"3204_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1159\/000439101","volume":"33","author":"M Kudo","year":"2015","unstructured":"Kudo M, Kitano M, Sakurai T, Nishida N. General rules for the clinical and pathological study of primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. Dig Dis. 2015;33(6):765\u201370.","journal-title":"Dig Dis"},{"issue":"2","key":"3204_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288\u2013306.","journal-title":"J Hepatol"},{"issue":"5","key":"3204_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1478-3231.2011.02734.x","volume":"32","author":"K Migita","year":"2012","unstructured":"Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, Ohta H, Shimada M, Mita E, Hijioka T, et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int. 2012;32(5):837\u201344.","journal-title":"Liver Int"},{"key":"3204_CR15","doi-asserted-by":"crossref","unstructured":"Colapietro F, Maisonneuve P, Lytvyak E, Beuers U, Verdonk RC, van der Meer AJ, van Hoek B, Kuiken SD, Brouwer JT, Muratori P et al. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis. J Hepatol 2023.","DOI":"10.1016\/j.dld.2023.01.015"},{"issue":"6","key":"3204_CR16","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/hep.1840080635","volume":"8","author":"KK Wang","year":"1988","unstructured":"Wang KK, Czaja AJ. Hepatocellular carcinoma in corticosteroid-treated severe autoimmune chronic active hepatitis. Hepatology. 1988;8(6):1679\u201383.","journal-title":"Hepatology"},{"key":"3204_CR17","doi-asserted-by":"crossref","unstructured":"Rigopoulou EI, Dalekos GN. Current trends and Characteristics of Hepatocellular Carcinoma in patients with Autoimmune Liver diseases. Cancers (Basel) 2021, 13(5).","DOI":"10.3390\/cancers13051023"},{"issue":"2","key":"3204_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/hep.25658","volume":"56","author":"K Yoshizawa","year":"2012","unstructured":"Yoshizawa K, Matsumoto A, Ichijo T, Umemura T, Joshita S, Komatsu M, Tanaka N, Tanaka E, Ota M, Katsuyama Y, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology. 2012;56(2):668\u201376.","journal-title":"Hepatology"},{"issue":"8","key":"3204_CR19","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1111\/j.1572-0241.2008.01922.x","volume":"103","author":"AJ Montano-Loza","year":"2008","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008;103(8):1944\u201351.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"3204_CR20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/j.1365-2036.2006.03113.x","volume":"24","author":"Y Miyake","year":"2006","unstructured":"Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2006;24(8):1197\u2013205.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"3204_CR21","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/hep4.1923","volume":"6","author":"RF Reveron-Thornton","year":"2022","unstructured":"Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, et al. Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies. Hepatol Commun. 2022;6(7):1813\u201326.","journal-title":"Hepatol Commun"},{"key":"3204_CR22","doi-asserted-by":"crossref","unstructured":"Harrison L, Hoeroldt B, Dhaliwal H, Wadland E, Dube A, Gleeson D. Long-term outcome of Autoimmune Hepatitis: consecutive patient cohort and data on the second twenty years. Dig Liver Dis; 2023.","DOI":"10.1016\/j.dld.2023.06.014"},{"issue":"22","key":"3204_CR23","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.3748\/wjg.v27.i22.2994","volume":"27","author":"A Granito","year":"2021","unstructured":"Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, Lenzi M, Muratori P. Hepatocellular carcinoma in viral and autoimmune liver diseases: role of CD4\u2009+\u2009CD25\u2009+\u2009Foxp3\u2009+\u2009regulatory T cells in the immune microenvironment. World J Gastroenterol. 2021;27(22):2994\u20133009.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3204_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3350\/cmh.2020.0189","volume":"27","author":"A Komori","year":"2021","unstructured":"Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol. 2021;27(1):58\u201369.","journal-title":"Clin Mol Hepatol"},{"issue":"7","key":"3204_CR25","first-page":"e16570","volume":"13","author":"A Hokama","year":"2021","unstructured":"Hokama A, Arakaki S, Ishino S, Nakagawa Y, Tabata S, Agarie D, Kuwae S, Zukeyama R, Maeshiro T, Tsuruta Y, et al. Hepatocellular Carcinoma in a patient with Crohn\u2019s Disease. Cureus. 2021;13(7):e16570.","journal-title":"Cureus"},{"issue":"1","key":"3204_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","volume":"70","author":"M Pinter","year":"2021","unstructured":"Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut. 2021;70(1):204\u201314.","journal-title":"Gut"},{"key":"3204_CR27","doi-asserted-by":"crossref","unstructured":"Hamaya S, Oura K, Morishita A, Masaki T. Cisplatin in Liver Cancer Therapy. Int J Mol Sci 2023, 24(13).","DOI":"10.3390\/ijms241310858"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03204-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03204-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T17:01:50Z","timestamp":1711990910000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03204-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3204"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03204-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in compliance with the \u201cDeclaration of Helsinki\u201d and the \u201cEthical Guidelines for Clinical Trials in Medical Research Involving Human Subjects\u201d and was authorized by the Ethics Committee of Kagawa University School of Medicine (Ethics Committee Reception Number 2019\u2009\u2212\u2009238). As a retrospective study, informed consent was waived by the Ethics Committee of Kagawa University School of Medicine. The objectives and methods of the study were revealed in an opt-out basis, and the participants were given the opportunity to refuse the use of their medical identifiers at their request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}